 | • レポートコード：D005-00431 • 出版社/出版日：GlobalInfoResearch / 2020年5月29日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、108ページ • 納品方法：Eメール • 産業分類：医療・製薬 |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、胃食道逆流症（GERD）治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。胃食道逆流症（GERD）治療の種類別市場規模（制酸剤、運動促進剤、H2受容体遮断薬、プロトンポンプ阻害剤（PPI））、用途別市場規模（胸焼け、酸逆流症）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：AstraZeneca、Takeda、Eisai、GSK、Johnson & Johnson ・地域別グローバル市場分析 2015年-2020年 ・胃食道逆流症（GERD）治療の北米市場（アメリカ、カナダ、メキシコ） ・胃食道逆流症（GERD）治療のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・胃食道逆流症（GERD）治療のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・胃食道逆流症（GERD）治療の南米市場（ブラジル、アルゼンチン） ・胃食道逆流症（GERD）治療の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：制酸剤、運動促進剤、H2受容体遮断薬、プロトンポンプ阻害剤（PPI） ・用途別分析：胸焼け、酸逆流症 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global Gastroesophageal Reflux Disease (GERD) Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 0.6% in the forecast period of 2020 to 2025 and will expected to reach USD 4989.6 million by 2025, from USD 4870.2 million in 2019.
The Gastroesophageal Reflux Disease (GERD) Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Gastroesophageal Reflux Disease (GERD) Therapeutics market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Gastroesophageal Reflux Disease (GERD) Therapeutics market has been segmented into:
Antacids
Pro-kinetic agents
H2 Receptor Blockers
Proton Pump Inhibitors (PPIs)
By Application, Gastroesophageal Reflux Disease (GERD) Therapeutics has been segmented into:
Heartburn
Acid reflux disorders
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Gastroesophageal Reflux Disease (GERD) Therapeutics market presented in the report. This section sheds light on the sales growth of different regional and country-level Gastroesophageal Reflux Disease (GERD) Therapeutics markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Gastroesophageal Reflux Disease (GERD) Therapeutics market.
The report offers in-depth assessment of the growth and other aspects of the Gastroesophageal Reflux Disease (GERD) Therapeutics market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Gastroesophageal Reflux Disease (GERD) Therapeutics Market Share Analysis
Gastroesophageal Reflux Disease (GERD) Therapeutics competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Gastroesophageal Reflux Disease (GERD) Therapeutics sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Gastroesophageal Reflux Disease (GERD) Therapeutics sales, revenue and market share for each player covered in this report.
The major players covered in Gastroesophageal Reflux Disease (GERD) Therapeutics are:
AstraZeneca
Takeda
Eisai
GSK
Johnson & Johnson
Table of Contents
1 Gastroesophageal Reflux Disease (GERD) Therapeutics Market Overview
1.1 Product Overview and Scope of Gastroesophageal Reflux Disease (GERD) Therapeutics
1.2 Classification of Gastroesophageal Reflux Disease (GERD) Therapeutics by Type
1.2.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Type in 2019
1.2.3 Antacids
1.2.4 Pro-kinetic agents
1.2.5 H2 Receptor Blockers
1.2.6 Proton Pump Inhibitors (PPIs)
1.3 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market by Application
1.3.1 Overview: Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Heartburn
1.3.3 Acid reflux disorders
1.4 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market by Regions
1.4.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Gastroesophageal Reflux Disease (GERD) Therapeutics (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Gastroesophageal Reflux Disease (GERD) Therapeutics Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Gastroesophageal Reflux Disease (GERD) Therapeutics Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Gastroesophageal Reflux Disease (GERD) Therapeutics Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Gastroesophageal Reflux Disease (GERD) Therapeutics Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Gastroesophageal Reflux Disease (GERD) Therapeutics Status and Prospect (2015-2025)
2 Company Profiles
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 AstraZeneca SWOT Analysis
2.1.4 AstraZeneca Product and Services
2.1.5 AstraZeneca Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.2 Takeda
2.2.1 Takeda Details
2.2.2 Takeda Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Takeda SWOT Analysis
2.2.4 Takeda Product and Services
2.2.5 Takeda Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.3 Eisai
2.3.1 Eisai Details
2.3.2 Eisai Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Eisai SWOT Analysis
2.3.4 Eisai Product and Services
2.3.5 Eisai Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.4 GSK
2.4.1 GSK Details
2.4.2 GSK Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 GSK SWOT Analysis
2.4.4 GSK Product and Services
2.4.5 GSK Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.5 Johnson & Johnson
2.5.1 Johnson & Johnson Details
2.5.2 Johnson & Johnson Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Johnson & Johnson SWOT Analysis
2.5.4 Johnson & Johnson Product and Services
2.5.5 Johnson & Johnson Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Gastroesophageal Reflux Disease (GERD) Therapeutics Players Market Share
3.2.2 Top 10 Gastroesophageal Reflux Disease (GERD) Therapeutics Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Market Share by Regions
4.2 North America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
4.3 Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
4.5 South America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
5 North America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Countries
5.1 North America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Countries (2015-2020)
5.2 USA Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
5.3 Canada Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
5.4 Mexico Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
6 Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Countries
6.1 Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Countries (2015-2020)
6.2 Germany Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
6.3 UK Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
6.4 France Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
6.5 Russia Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
6.6 Italy Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Countries
7.1 Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Countries (2015-2020)
7.2 China Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
7.3 Japan Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
7.4 Korea Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
7.5 India Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
8 South America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Countries
8.1 South America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Countries (2015-2020)
8.2 Brazil Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
8.3 Argentina Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Gastroesophageal Reflux Disease (GERD) Therapeutics by Countries
9.1 Middle East & Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Countries (2015-2020)
9.2 Saudi Arabia Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
9.3 UAE Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
9.4 Egypt Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
9.5 South Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Market Share by Type (2015-2020)
10.2 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Forecast by Type (2019-2024)
10.3 Antacids Revenue Growth Rate (2015-2025)
10.4 Pro-kinetic agents Revenue Growth Rate (2015-2025)
10.5 H2 Receptor Blockers Revenue Growth Rate (2015-2025)
10.6 Proton Pump Inhibitors (PPIs) Revenue Growth Rate (2015-2025)
11 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Segment by Application
11.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Application (2015-2020)
11.2 Gastroesophageal Reflux Disease (GERD) Therapeutics Market Forecast by Application (2019-2024)
11.3 Heartburn Revenue Growth (2015-2020)
11.4 Acid reflux disorders Revenue Growth (2015-2020)
12 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size Forecast (2021-2025)
12.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size Forecast (2021-2025)
12.2 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Forecast by Regions (2021-2025)
12.3 North America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Forecast (2021-2025)
12.4 Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Forecast (2021-2025)
12.6 South America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Gastroesophageal Reflux Disease (GERD) Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. AstraZeneca Corporate Information, Location and Competitors
Table 6. AstraZeneca Gastroesophageal Reflux Disease (GERD) Therapeutics Major Business
Table 7. AstraZeneca Gastroesophageal Reflux Disease (GERD) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 8. AstraZeneca SWOT Analysis
Table 9. AstraZeneca Gastroesophageal Reflux Disease (GERD) Therapeutics Product and Solutions
Table 10. AstraZeneca Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Takeda Corporate Information, Location and Competitors
Table 12. Takeda Gastroesophageal Reflux Disease (GERD) Therapeutics Major Business
Table 13. Takeda Gastroesophageal Reflux Disease (GERD) Therapeutics Total Revenue (USD Million) (2018-2019)
Table 14. Takeda SWOT Analysis
Table 15. Takeda Gastroesophageal Reflux Disease (GERD) Therapeutics Product and Solutions
Table 16. Takeda Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Eisai Corporate Information, Location and Competitors
Table 18. Eisai Gastroesophageal Reflux Disease (GERD) Therapeutics Major Business
Table 19. Eisai Gastroesophageal Reflux Disease (GERD) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 20. Eisai SWOT Analysis
Table 21. Eisai Gastroesophageal Reflux Disease (GERD) Therapeutics Product and Solutions
Table 22. Eisai Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. GSK Corporate Information, Location and Competitors
Table 24. GSK Gastroesophageal Reflux Disease (GERD) Therapeutics Major Business
Table 25. GSK Gastroesophageal Reflux Disease (GERD) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 26. GSK SWOT Analysis
Table 27. GSK Gastroesophageal Reflux Disease (GERD) Therapeutics Product and Solutions
Table 28. GSK Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Johnson & Johnson Corporate Information, Location and Competitors
Table 30. Johnson & Johnson Gastroesophageal Reflux Disease (GERD) Therapeutics Major Business
Table 31. Johnson & Johnson Gastroesophageal Reflux Disease (GERD) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 32. Johnson & Johnson SWOT Analysis
Table 33. Johnson & Johnson Gastroesophageal Reflux Disease (GERD) Therapeutics Product and Solutions
Table 34. Johnson & Johnson Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (Million USD) by Players (2015-2020)
Table 36. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Share by Players (2015-2020)
Table 37. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (Million USD) by Regions (2015-2020)
Table 38. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Regions (2015-2020)
Table 39. North America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Countries (2015-2020)
Table 40. North America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Countries (2015-2020)
Table 41. Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 42. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 43. South America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Countries (2015-2020)
Table 44. South America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Countries (2015-2020)
Table 45. Middle East and Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 46. Middle East and Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Countries (2015-2020)
Table 47. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (Million USD) by Type (2015-2020)
Table 48. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Share by Type (2015-2020)
Table 49. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Forecast by Type (2021-2025)
Table 50. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Application (2015-2020)
Table 51. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Share by Application (2015-2020)
Table 52. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Forecast by Application (2021-2025)
Table 53. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Gastroesophageal Reflux Disease (GERD) Therapeutics Picture
Figure 2. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Type in 2019
Figure 3. Antacids Picture
Figure 4. Pro-kinetic agents Picture
Figure 5. H2 Receptor Blockers Picture
Figure 6. Proton Pump Inhibitors (PPIs) Picture
Figure 7. Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Application in 2019
Figure 8. Heartburn Picture
Figure 9. Acid reflux disorders Picture
Figure 10. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (USD Million) and Growth Rate (2015-2025)
Figure 11. North America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. South America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Middle East and Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Share by Players in 2019
Figure 18. Global Top 5 Players Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share in 2019
Figure 19. Global Top 10 Players Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share in 2019
Figure 20. Key Players Market Share Trend
Figure 21. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 22. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Regions (2015-2020)
Figure 23. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Regions in 2018
Figure 24. North America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 25. Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 26. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 27. South America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 28. Middle East and Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 29. North America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 30. North America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Countries in 2019
Figure 31. USA Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 32. Canada Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 33. Mexico Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 34. Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 35. Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Countries in 2019
Figure 36. Germany Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 37. UK Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 38. France Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 39. Russia Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 40. Italy Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 41. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 42. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Countries in 2019
Figure 43. China Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 44. Japan Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 45. Korea Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 46. India Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 47. Southeast Asia Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 48. South America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 49. South America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Countries in 2019
Figure 50. Brazil Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 51. Argentina Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 52. Middle East and Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 53. Middle East and Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Countries in 2019
Figure 54. Saudi Arabia Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 55. UAE Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 56. Egypt Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 57. South Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 58. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Share by Type (2015-2020)
Figure 59. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Share by Type in 2019
Figure 60. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Share Forecast by Type (2021-2025)
Figure 61. Global Antacids Revenue Growth Rate (2015-2020)
Figure 62. Global Pro-kinetic agents Revenue Growth Rate (2015-2020)
Figure 63. Global H2 Receptor Blockers Revenue Growth Rate (2015-2020)
Figure 64. Global Proton Pump Inhibitors (PPIs) Revenue Growth Rate (2015-2020)
Figure 65. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Share by Application (2015-2020)
Figure 66. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Share by Application in 2019
Figure 67. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Share Forecast by Application (2021-2025)
Figure 68. Global Heartburn Revenue Growth Rate (2015-2020)
Figure 69. Global Acid reflux disorders Revenue Growth Rate (2015-2020)
Figure 70. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 71. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 72. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share Forecast by Regions (2021-2025)
Figure 73. North America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Forecast (2021-2025)
Figure 74. Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Forecast (2021-2025)
Figure 75. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Forecast (2021-2025)
Figure 76. South America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Forecast (2021-2025)
Figure 77. Middle East and Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Forecast (2021-2025)
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
胃食道逆流症（GERD）薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Gastro Esophageal Reflux Disease (GERD) Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The …- ウィルソン病治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Wilson`s Disease Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 5.7% in the forecast period of 2020 to 2025 and will expected to reach USD 504.3 million by 2025, from USD 403.3 million in 2019. The Wilson`s Di…
- クラッベ病治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Krabbe Disease Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Krabbe Disease Treat…
- ライム病ワクチンの世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Lyme Disease Vaccine market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Lyme Disease Vaccine mar…
- 腸疾患検査＆治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Enteric Disease Testing and Therapeutic market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 1.4% in the forecast period of 2020 to 2025 and will expected to reach USD 3273.4 million by 2025, from USD 3101.6 million in 2019. …